Skip to content

Aqilion presents Nomination Committee for the 2023 Annual General Meeting

The Nomination Committee for the 2023 Annual General Meeting has been appointed and comprises the following members:

  • Christian Ewe, appointed by the shareholder LMK Forward AB
  • Linus Wiebe, appointed by the shareholder Fåhraeus Start Up and Growth AB
  • Katarina Berggren, appointed by the shareholder Grenspecialisten AB

The members appoint the Chairman among themselves.

The Nomination Committee shall prepare proposals for the 2023 Annual General Meeting regarding the Chairman of the meeting, election of Board members and Chairman of the Board, the fees to be paid to the Board Chairman and the Board members, remuneration to the auditor and election of the auditor.

The Annual General Meeting of AQILION AB (publ) will be held on Thursday, June 1, 2023, at 05.00 p.m. (CET) in Helsingborg, Sweden.

For more information, please contact:
Sarah Fredriksson, CEO, AQILION AB, + 46 (0)70 261 4575,

About Aqilion
Aqilion is a biotech company that focuses on developing new innovative treatments for diseases caused by chronic inflammation and dysfunctional immune reactions such as autoimmune diseases. The company is mainly active in the early phases of drug discovery, from idea to early clinical development.

Aqilion combines its experience from major pharmaceutical companies with the drive and entrepreneurship of small growth companies. With solid experience of business development in innovative biotech and pharmaceutical companies, Aqilion’s experienced team and board have successfully shepherded drugs all the way from discovery to market.

AQILION AB (publ) is a Swedish public limited company headquartered in Helsingborg, Sweden.